AU2002242226B2 - Carbamate compounds for use in preventing or treating bipolar disorder - Google Patents
Carbamate compounds for use in preventing or treating bipolar disorder Download PDFInfo
- Publication number
- AU2002242226B2 AU2002242226B2 AU2002242226A AU2002242226A AU2002242226B2 AU 2002242226 B2 AU2002242226 B2 AU 2002242226B2 AU 2002242226 A AU2002242226 A AU 2002242226A AU 2002242226 A AU2002242226 A AU 2002242226A AU 2002242226 B2 AU2002242226 B2 AU 2002242226B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- enantiomer
- sub
- bipolar disorder
- predominates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000020925 Bipolar disease Diseases 0.000 title claims abstract description 54
- 150000004657 carbamic acid derivatives Chemical class 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 25
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 17
- 239000001257 hydrogen Substances 0.000 claims abstract description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000460 chlorine Substances 0.000 claims abstract description 13
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 150000002367 halogens Chemical group 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 7
- 239000011737 fluorine Substances 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 239000011630 iodine Substances 0.000 claims abstract description 6
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 6
- 206010026749 Mania Diseases 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 230000001351 cycling effect Effects 0.000 claims description 7
- 206010021030 Hypomania Diseases 0.000 claims description 4
- 208000028683 bipolar I disease Diseases 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 208000026725 cyclothymic disease Diseases 0.000 claims description 3
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 206010010904 Convulsion Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 239000004050 mood stabilizer Substances 0.000 description 5
- 229940127237 mood stabilizer Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001535 kindling effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940125681 anticonvulsant agent Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 phenyl alkyl carbamate compounds Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940102566 valproate Drugs 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QTWMTAXHUBXJQF-UHFFFAOYSA-N (2-carbamoyloxy-2-phenylethyl) carbamate Chemical class NC(=O)OCC(OC(N)=O)C1=CC=CC=C1 QTWMTAXHUBXJQF-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018671 Grandiosity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010064805 Tachyphrenia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical class NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168001P | 2001-02-27 | 2001-02-27 | |
| US60/271,680 | 2001-02-27 | ||
| US10/081,606 | 2002-02-21 | ||
| PCT/US2002/005425 WO2002067924A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating bipolar disorder |
| US10/081,606 US7122576B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating bipolar disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002242226A1 AU2002242226A1 (en) | 2003-03-06 |
| AU2002242226B2 true AU2002242226B2 (en) | 2006-06-29 |
Family
ID=26765743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002242226A Ceased AU2002242226B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating bipolar disorder |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7122576B2 (enExample) |
| EP (1) | EP1368021B1 (enExample) |
| JP (1) | JP4276839B2 (enExample) |
| KR (1) | KR20030074849A (enExample) |
| CN (1) | CN1250214C (enExample) |
| AT (1) | ATE378046T1 (enExample) |
| AU (1) | AU2002242226B2 (enExample) |
| BR (1) | BR0207832A (enExample) |
| CA (1) | CA2439292A1 (enExample) |
| CY (1) | CY1107199T1 (enExample) |
| CZ (1) | CZ296641B6 (enExample) |
| DE (1) | DE60223506T2 (enExample) |
| DK (1) | DK1368021T3 (enExample) |
| ES (1) | ES2295320T3 (enExample) |
| HU (1) | HUP0303261A3 (enExample) |
| IL (2) | IL157589A0 (enExample) |
| MX (1) | MXPA03007716A (enExample) |
| MY (1) | MY133370A (enExample) |
| NO (1) | NO20033799L (enExample) |
| NZ (1) | NZ527989A (enExample) |
| PL (1) | PL364640A1 (enExample) |
| PT (1) | PT1368021E (enExample) |
| RS (1) | RS50680B (enExample) |
| RU (1) | RU2286147C2 (enExample) |
| WO (1) | WO2002067924A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51269B (sr) * | 2004-09-16 | 2010-12-31 | Janssen Pharmaceutica N.V. | Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze |
| FR2884714B1 (fr) * | 2005-04-20 | 2011-05-06 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires |
| US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
| BRPI0520451A2 (pt) * | 2005-07-26 | 2009-05-12 | Janssen Pharmaceutica Nv | métodos para tratamento de distúrbios associados a substáncias quìmicas |
| CN101568362A (zh) * | 2006-10-30 | 2009-10-28 | 詹森药业有限公司 | 治疗抑郁症的方法 |
| HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| HUP0700370A2 (en) * | 2007-05-24 | 2009-04-28 | Richter Gedeon Nyrt | Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| EA023972B1 (ru) * | 2008-02-21 | 2016-08-31 | Рихтер Гедеон Нирт. | Стабильный твёрдый препарат карипразина для перорального введения и способ его получения |
| HRP20150196T1 (hr) | 2008-07-16 | 2015-06-05 | Richter Gedeon Nyrt. | Farmaceutske formulacije s ligandima receptora dopamina |
| HU230067B1 (hu) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| WO2018111008A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
-
2002
- 2002-02-21 BR BR0207832-5A patent/BR0207832A/pt not_active Application Discontinuation
- 2002-02-21 CZ CZ20032312A patent/CZ296641B6/cs not_active IP Right Cessation
- 2002-02-21 NZ NZ527989A patent/NZ527989A/en not_active IP Right Cessation
- 2002-02-21 IL IL15758902A patent/IL157589A0/xx unknown
- 2002-02-21 DK DK02707850T patent/DK1368021T3/da active
- 2002-02-21 RS YUP-680/03A patent/RS50680B/sr unknown
- 2002-02-21 KR KR10-2003-7011290A patent/KR20030074849A/ko not_active Ceased
- 2002-02-21 EP EP02707850A patent/EP1368021B1/en not_active Expired - Lifetime
- 2002-02-21 MX MXPA03007716A patent/MXPA03007716A/es active IP Right Grant
- 2002-02-21 PT PT02707850T patent/PT1368021E/pt unknown
- 2002-02-21 CN CNB02808716XA patent/CN1250214C/zh not_active Expired - Fee Related
- 2002-02-21 DE DE60223506T patent/DE60223506T2/de not_active Expired - Lifetime
- 2002-02-21 US US10/081,606 patent/US7122576B2/en not_active Expired - Fee Related
- 2002-02-21 WO PCT/US2002/005425 patent/WO2002067924A1/en not_active Ceased
- 2002-02-21 CA CA002439292A patent/CA2439292A1/en not_active Abandoned
- 2002-02-21 PL PL02364640A patent/PL364640A1/xx not_active Application Discontinuation
- 2002-02-21 JP JP2002567291A patent/JP4276839B2/ja not_active Expired - Fee Related
- 2002-02-21 AT AT02707850T patent/ATE378046T1/de active
- 2002-02-21 HU HU0303261A patent/HUP0303261A3/hu unknown
- 2002-02-21 RU RU2003128996/14A patent/RU2286147C2/ru not_active IP Right Cessation
- 2002-02-21 AU AU2002242226A patent/AU2002242226B2/en not_active Ceased
- 2002-02-21 ES ES02707850T patent/ES2295320T3/es not_active Expired - Lifetime
- 2002-02-27 MY MYPI20020694A patent/MY133370A/en unknown
-
2003
- 2003-08-26 IL IL157589A patent/IL157589A/en active IP Right Grant
- 2003-08-26 NO NO20033799A patent/NO20033799L/no not_active Application Discontinuation
-
2008
- 2008-02-14 CY CY20081100183T patent/CY1107199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002242226B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| EP1408953B1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| US6589985B2 (en) | Carbamate compounds for use in preventing or treating movement disorders | |
| AU2002242226A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AU2002255580B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AU2002354909B2 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| HK1058762B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| AU2002255580A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| HK1063436B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| HK1063288B (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
| HK1067305B (en) | Carbamate compounds for use in preventing or treating movement disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |